Want to see SRRK full AI Analyst Report?
SRRK Stock Chart & Stats
$49.96
-$0.51(-1.26%)
At close: 4:00 PM EST
$49.96
-$0.51(-1.26%)
Day’s Range― - ―
52-Week Range$27.07 - $58.49
Previous CloseN/A
Volume133.12K
Average Volume (3M)1.54M
Market Cap
$6.33B
Enterprise Value$5.98K
Total Cash (Recent Filing)$479.94M
Total Debt (Recent Filing)$205.67M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Aug 06, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.45
Shares Outstanding119,828,340
10 Day Avg. Volume990,601
30 Day Avg. Volume1,536,287
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)20.58
Price to Sales (P/S)0.00
P/FCF Ratio-16.81
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$59.56Price Target Upside19.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.16
Revenue Forecast (FY)$6.27M
Bulls Say, Bears Say
Bulls Say
Regulatory Progress (BLA Accepted)FDA acceptance with a defined PDUFA date converts a speculative outcome into a time‑bound regulatory milestone. This reduces long‑term uncertainty, enables disciplined commercial planning, payer engagement, and manufacturing timing, and materially improves the company's ability to execute a coordinated launch strategy.
Dual Manufacturing / Supply RedundancyHaving two independent fill‑finish paths and a second facility ready for early Q3 supply materially lowers single‑site dependency. This structural redundancy reduces launch failure risk from supply disruption, supports reliable patient access at commercialization, and strengthens operational resilience over the coming quarters.
Strong Near‑term Liquidity And Financing OptionalityA sizeable cash balance plus recent raises and contingent financing options provide a substantive runway into potential approval and initial commercialization. This durable liquidity and structured optionality reduce immediate financing pressure, enabling investment in launch infrastructure and clinical programs without immediate dilutive events.
Bears Say
No Product Revenue; Heavy Cash BurnThe company remains pre‑revenue with accelerating losses and large negative operating cash flow. Over the medium term this persistent cash burn mandates ongoing access to capital markets or milestone monetization; failure to convert regulatory success into sustained sales would amplify dilution and threaten execution of strategic plans.
Rising Leverage And Dependence On FinancingDebt has meaningfully increased, lifting leverage and constraining flexibility. Elevated indebtedness raises interest and covenant exposure and makes the company more vulnerable to tightening credit or higher funding costs, particularly if commercial revenues lag and cash burn remains elevated over multiple quarters.
Manufacturing/regulatory Contingency At Catalent IndianaThe pending classification of Catalent Indiana creates a structural approval and supply contingency. An adverse classification could delay U.S. approval or complicate EU timelines, force alternative sourcing, or restrict label/commercial timing—each materially affecting launch sequencing and near‑term revenue realization.
Scholar Rock Holding News
SRRK FAQ
What was Scholar Rock Holding’s price range in the past 12 months?
Scholar Rock Holding lowest stock price was $27.07 and its highest was $58.49 in the past 12 months.
What is Scholar Rock Holding’s market cap?
Scholar Rock Holding’s market cap is $6.33B.
When is Scholar Rock Holding’s upcoming earnings report date?
Scholar Rock Holding’s upcoming earnings report date is Aug 06, 2026 which is in 16 days.
How were Scholar Rock Holding’s earnings last quarter?
Scholar Rock Holding released its earnings results on May 07, 2026. The company reported -$0.83 earnings per share for the quarter, missing the consensus estimate of -$0.8 by -$0.03.
Is Scholar Rock Holding overvalued?
According to Wall Street analysts Scholar Rock Holding’s price is currently Undervalued.
Does Scholar Rock Holding pay dividends?
Scholar Rock Holding does not currently pay dividends.
What is Scholar Rock Holding’s EPS estimate?
Scholar Rock Holding’s EPS estimate is -0.84.
How many shares outstanding does Scholar Rock Holding have?
Scholar Rock Holding has 119,828,340 shares outstanding.
What happened to Scholar Rock Holding’s price movement after its last earnings report?
Scholar Rock Holding reported an EPS of -$0.83 in its last earnings report, missing expectations of -$0.8. Following the earnings report the stock price went down -1.401%.
Which hedge fund is a major shareholder of Scholar Rock Holding?
Currently, no hedge funds are holding shares in SRRK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Scholar Rock Holding Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$59.56 (19.21% Upside)
$59.56 (19.21% Upside)
Blogger Sentiment
Bullish
SRRK Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 183.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 9.6%
Last 30 Days ▼ 9.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.41%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
31.33%
Trailing 12-Months
Company Description
Scholar Rock Holding
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
SRRK Stock 12 Month Forecast
Average Price Target
$59.56
▲(19.21% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Viking Therapeutics
―
Xenon
―
Immunovant
―
NewAmsterdam Pharma Company
―
Ownership Overview
20.63% Insiders
30.07% Mutual Funds
0.28% Other Institutional Investors
36.65% Public Companies and
Individual Investors